Insider buying last 90 days
No open-market insider purchases were filed for NTLA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NTLA insider filing, plotted on the chart in Gekko.Open NTLA in Gekko
NASDAQ: NTLA
Intellia Therapeutics (NTLA) Stock Analysis & Forecast
Oct 12 close
$12.58−0.49 (−3.7%)
Gekko Brief
AI summaryOct 12 closeThis week's moves for Intellia center on regulatory progress and analyst positioning. The FDA accepted the biologics license application for lonvoguran ziclumeran with Priority Review, and the company secured a $400 million debt facility, both framed as shifting the narrative toward commercialization funding. Barclays initiated coverage with an Underweight rating and an $8.00 price target, reiterating a Sell stance, while shares have also drawn comparisons against peer UTHR on profitability and valuation grounds.
NTLA closed at $12.58, down 3.7%, sitting between its 50-day average of $12.22 and 200-day average of $12.95, a mixed trend signal. The GekkoIndex reads 54.6, placing the stock in the Neutral zone, with a five-point change of -1.4. Gekko Fair Value stands at $16.36, putting the current price 23.1% below that level.
Looking ahead, Intellia reports earnings on 5 November 2026, before the open, 24 days away and inside a typical 20-trading-day holding period; the prior quarter's EPS matched estimates at -0.8 with an 8.8% reaction, against an average absolute reaction of 8.7% across prior reports. Analyst views remain split, with 6 buy, 5 hold and 3 sell ratings among 14 firms, and a consensus target of $23.11. Seasonality from this point has averaged -15% over 20 trading days across 5 years, rising in just 1 of them, a pattern worth noting alongside the upcoming earnings date.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Intellia Therapeutics price vs fair value
Close $12.58200-day averageGekko Fair Value $16.36
Intellia Therapeutics quick facts
- Market cap
- $1.76B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.35
- Revenue, TTM
- $59.51M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.80
- Volume
- 4.36M avg 5.81M
- 1-year return
- −50.6%
- Typical daily move
- ±6.4%
- Typical 20-day move
- ±11.4%
- 50-day average
- $12.22
- 200-day average
- $12.95
- Next earnings
- Nov 5 before open
- Shares outstanding
- 140.1M
Intellia Therapeutics swing-trade checklist
Intellia Therapeutics scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed2 headwinds
- Trendmixed
Averages disagree
Close $12.58 sits between the 50-day ($12.22) and 200-day ($12.95) averages, or the averages disagree.
See the chart - GekkoIndexmixed
54.6, Neutral
Reading 54.6 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
23.1% below
Price is 23.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−15.0% on average
From this point in the calendar, the next 20 trading days averaged −15% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Intellia Therapeutics stock chart and price history
Intellia Therapeutics closed at $12.58 on Oct 12, 2026, −50.6% over the past year, inside a 52-week range of $7.95 to $28.25.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +7.2%
- 3 months
- −5.4%
- 6 months
- −11.8%
- 1 year
- −50.6%
The full NTLA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NTLA in Gekko
Follow Intellia Therapeutics through every session
Put NTLA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NTLA in GekkoFree for 7 days. No credit card required.
About Intellia Therapeutics
Intellia Therapeutics works on medicines built around genome editing, using the CRISPR/Cas9 system to design treatments for serious diseases. It is known for programs delivered directly inside the body, including candidates aimed at transthyretin amyloidosis and hereditary angioedema, alongside liver-focused work targeting hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. It also develops therapies that modify cells outside the body, such as a candidate for acute myeloid leukemia, plus engineered cell therapies aimed at cancers and autoimmune conditions.
Much of this work is carried out through partnerships rather than alone. Intellia has a collaboration with Novartis Institutes for BioMedical Research to engineer stem cells for sickle cell disease, a co-development agreement with Regeneron Pharmaceuticals covering hemophilia A and B, research ties with Ospedale San Raffaele, and an alliance with SparingVision aimed at genomic treatments for eye diseases.
Originally known as AZRN, Inc., the company was founded in 2014 and is headquartered in Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker NTLA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- intelliatx.com
Intellia Therapeutics GekkoIndex: the smart money zone
Intellia Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.6, in the Neutral zone, down 1.4 points over five sessions.
54.6Neutral
Down 1.4 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 63 | +2.9% | +6.4% | ||
| Accumulation | 273 | +0.1% | +0.4% | ||
| Neutral (current zone) | 309 | −0.9% | +0.5% | ||
| Distribution | 35 | +5.8% | −6.3% | ||
| Selling | 2 | Too few readings yet | |||
Average NTLA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the NTLA price, zone by zone.Track NTLA in Gekko
Is Intellia Therapeutics stock overvalued? Gekko Fair Value
Intellia Therapeutics trades 23.1% below Gekko Fair Value of $16.36, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Intellia Therapeutics shares are worth, recalculated every trading day.
$16.36
Gekko Fair Value, Oct 10, 2026
23.1% Undervalued
At the end of Aug 2026 the price was 36.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NTLA in Gekko
Intellia Therapeutics insider and Congress trading
No open-market insider purchases were filed for Intellia Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NTLA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NTLA, plotted on the chart in Gekko.Open NTLA in Gekko
Intellia Therapeutics earnings: next date and track record
Intellia Therapeutics reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- −$0.80
- Revenue estimate
- $9.74M
7 of 8reports beat the EPS estimate
±8.7%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Intellia reported strong Phase III HAELO trial results for lonvo-z in HAE, achieving 87% reduction in mean monthly attacks versus placebo, with 62% of patients attack-free and therapy-free. All primary and key secondary endpoints reached statistical significance. A BLA rolling submission is underway with FDA. The company is also advancing nex-z for ATTR with new genomic insights supporting competitive positioning.
- Guidance
- Intellia expects FDA BLA filing acceptance for lonvo-z by end of 2024, targeting a potential U.S. launch in the first half of 2025. Pre-commercial activities including field medical, reimbursement, and strategic accounts teams are fully hired and actively engaging treatment centers.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.80 est −$0.80 | $7.66M est $12.98M | +8.8% |
| May 11, 2026 | −$0.81 est −$0.90 | $15.05M est $13.81M | −0.7% |
| Feb 26, 2026 | −$0.83 est −$0.96 | $23.02M est $11.98M | +2.7% |
| Nov 6, 2025 | −$0.92 est −$1.02 | $13.78M est $12.17M | −29.8% |
| Aug 7, 2025 | −$0.99 est −$1.03 | $14.25M est $14.06M | −5.1% |
| May 8, 2025 | −$1.10 est −$1.26 | $16.63M est $11.93M | +11.4% |
| Feb 27, 2025 | −$1.24 est −$1.32 | $12.87M est $10.86M | −6.6% |
| Nov 7, 2024 | −$1.34 est −$1.37 | $9.11M est $8.90M | +4.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Intellia Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Intellia Therapeutics is $23.11, +83.7% from the last close, from 14 firms rating the stock in the last 90 days.
$23.11consensus 12-month target, +83.7% from the last close
Now $12.58Avg $23.11
Low $8High $49
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 6 | Barclays | $8 | −36.4% |
| Oct 2 | Wells Fargo | $15 | +19.2% |
| Sep 9 | H.C. Wainwright | $25 | +98.7% |
| Sep 9 | Wedbush | $13 | +3.3% |
| Sep 4 | TD Cowen | — | — |
+0.5%average 20-day move after past Neutral readings
−15.0%average move over the next 20 trading days in the last 5 years
±6.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Intellia Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Intellia Therapeutics averaged −15.0% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.7% | 4 of 5 |
| Next 10 trading days | +0.3% | 3 of 5 |
| Next 15 trading days | −15.7% | 1 of 5 |
| Next 20 trading days | −15.0% | 1 of 5 |
| Next 30 trading days | −21.9% | 0 of 5 |
For scale, NTLA’s typical 20-trading-day move in either direction is about 11.4%.
Intellia Therapeutics market cap and key statistics
Intellia Therapeutics’s market cap is $1.76B and revenue of $59.51M over the last twelve months.
Valuation
- Market cap
- $1.76B
- EPS, TTM
- −$3.35
- Gekko Fair Value
- $16.36
Trading
- Volume
- 4.36M
- Avg volume, 20 days
- 5.81M
- 52-week high
- $28.25
- 52-week low
- $7.95
- Shares outstanding
- 140.1M
Financials
- Revenue, TTM
- $59.51M
- Profit margin
- 0%
- Return on equity
- -55.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.80
- Typical daily move
- ±6.4%
- Typical 20-day move
- ±11.4%
Intellia Therapeutics stock news this week
Coverage of Intellia Therapeutics this week reads neutral: 4 positive, 5 neutral and 3 negative headlines.
- Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)Defense World, Oct 12
- FDA Priority Review Could Be A Game Changer For Intellia Therapeutics Stock (NTLA)Simply Wall Street, Oct 10
- Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Yahoo Finance, Oct 9
- Intellia Therapeutics (NTLA) Pullback Puts Its CRISPR Valuation Story Back In FocusSimply Wall Street, Oct 8
- Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at BarclaysDefense World, Oct 8
- Barclays Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $8Moomoo, Oct 7
Intellia Therapeutics peers
Intellia Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Intellia Therapeutics stock FAQ
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.76B at the Oct 12, 2026 close of $12.58, with 140.1M shares outstanding.
What is the Intellia Therapeutics stock forecast?
The consensus analyst 12-month price target for Intellia Therapeutics is $23.11, +83.7% from the last close. Of the 14 firms that rated the stock in the last 90 days, 6 rate it a buy, 5 a hold and 3 a sell. Gekko doesn’t publish price predictions of its own.
Is Intellia Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Intellia Therapeutics is undervalued: the Oct 12, 2026 close of $12.58 is 23.1% below Gekko Fair Value of $16.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Intellia Therapeutics report earnings next?
Intellia Therapeutics is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of −$0.80 per share on revenue of $9.74M. Intellia Therapeutics beat the earnings estimate in 7 of its last 8 reports, moving 8.7% on average across the report.
What is Intellia Therapeutics’s 52-week high and low?
Intellia Therapeutics’s 52-week high is $28.25 and its 52-week low is $7.95; it closed at $12.58 on Oct 12, 2026, −50.6% over the past year. Over the last five years the shares peaked at $143.92 on Nov 8, 2021.
Is Intellia Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (fair value), 2 as mixed (trend and gekkoindex) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Intellia Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.